Advertisement
Advertisement
IPA
ImmunoPrecise Antibodies Ltd
0.639
USD+0.146
+29.61%
Jan 22, 15:58 UTC -5
Closed
...
ImmunoPrecise Antibodies Ltd Profile
About
Info & Links
CEO
--
Headquarters
Industry
Sector
Website
--
Auditor
--
Share holders
--
Employees
--
ImmunoPrecise Antibodies Ltd Statistics
Valuation Measures
Market Capitalization2
18.42M
Enterprise Value
27.86M
Enterprise Value/EBITDA(ttm)
-4.33
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
0.93
Price to Book(mrq)
0.64
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
50.09%
Operating Margin(ttm)
-114.50%
Profit Margin(ttm)
-111.28%
Return on Equity(ttm)
-73.74%
Return on Invested Capital(ttm)
-58.55%
Return on Assets(ttm)
-42.68%
Income Statement
Revenue(ttm)
17.70M
Revenue Per Share(ttm)
--
Gross Profit(ttm)
8.89M
EBITDA(ttm)3
-6.44M
Net Income Available to Common(ttm)
-20.32M
Diluted EPS(ttm)
-0.78
Share Statistics
Beta (5Y Monthly)
0.01
52-Week Change
-60.90%
S&P 500 52-Week Change
25.12%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
--
Dividend Yield
0.00%
Float4
28.94M
% Held by Insiders
6.83%
% Held by Institutions
6.70%
Balance Sheet
Total Cash(mrq)
2.59M
Total Cash Per Share(mrq)
--
Total Debt(mrq)
12.03M
Total Debt/Equity(mrq)
50.26%
Current Ratio(mrq)
1.01%
Quick Ratio(mrq)
0.85%
Book Value Per Share(mrq)
0.79
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.11
Free Cash Flow(ytd)
-3.22M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement